A 7 years old female Murrah buffalo was presented to the Referral Veterinary Polyclinic, Indian Veterinary Research Institute, Izatnagar with a history of high fever, anorexia and respiratory distress since 2 days. On clinical examination, high body temperature, congested conjunctival mucous membrane, open mouth breathing, tachypnoea, tachycardia and lymphadenopathy noticed. Clinical pathology revealed leukocytosis, neutrophilia with shift to left and blood sample was found to be negative for haemoprotozoan infection. Bacteriological culture of blood sample revealed mucoid dew drop colonies suggestive of Pasteurella spp. and on Gram's staining of bacterial culture, Gram-negative cocco-bacilli organisms were detected. Further, the results of Pasteurella multocida species specific-PCR (polymerase chain reaction), Pasteurella multocida multiplex capsular PCR typing and Pasteurella multocida serotype B specific PCR revealed that the isolate was of Pasteurella multocida serotype B: 2. ABST (Antibiotic sensitivity test) revealed that the organism was highly sensitive for antibiotic Ceftiofur. The animal was treated with Inj. Ceftiofur sodium (2.2 mg/kg, IM, SID) and other supportive treatment including anti-pyretics, anti-histamines, multivitamins, rumenotorics and probiotics for 5 days. The animal showed marked recovery after complete therapy.

Haemorrhagic Septicaemia (HS) caused by Pasteurella multocidaserotype B:2 is an economically important disease of cattle and buffaloes, which causes heavy economic losses due to sudden death of animals in developing countries like Pakistan. In this country, animals were being vaccinated by alum (adjuvant) precipitated vaccine twice a year. Immunity induced through this prophylactic measure lasts for 3 to 4 months only, which reflect an un-protective state of the animals between two vaccinations. A new HS oil based vaccine has been developed by adding an adjuvant Montanide ISA-50V2 with the ratio of 1:1. The bacterial dry weight has been adjusted to 2 mg/ml which results in to reduction of dose per animal from 5 ml (alum precipitated) to 2 ml. The addition of enrichments and aeration (sparging and vortexing) has resulted in dense bacterial growth of Pasteurella multocida. The new vaccine has passed sterility, safety and potency tests as per OIE, 2017. This new product has low viscosity and single shot is expected to confer solid immunity against HS for one year. Active Mouse Protection Test, Passive Mouse Protection test and Indirect Haem-Agglutination Tests have been used to evaluate its potency. Properties like easy to inject with no side effects such as swelling at the injection site, have motivated the livestock owners to use this new product to protect their animals against fatal HS disease which will ultimately result in the increased productivity of livestock in Punjab, Pakistan.